Merck & Co has had mixed fortunes in neurological diseases of late ... structures that are used to break down and recycle waste products. TRPML is also thought to be a regulator of autophagy ...

and according to Merck has the potential to become a $3 billion product at peak for PAH, thanks to its to become the first drug for PAH that addresses the underlying disease process rather than ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...